Future care for long-term cancer survivors: towards a new model

M. Provencio; N. Romero; J. Tabernero; R. Vera; D. V. Baz; A. Arraiza; C. Camps; E. Felip; P. Garrido; B. Gaspar; M. Llombart; A. López; I. Magallón; V. M. Ibáñez; J. M. Olmos; C. Mur; A. Navarro-Ruiz; A. Pastor; M. Peiró Posadas; J. Polo; Rodríguez-Lescure

doi:10.1007/s12094-021-02696-5

Future care for long-term cancer survivors: towards a new model

M. Provencio, N. Romero, J. Tabernero, R. Vera, D. V. Baz, A. Arraiza, C. Camps, E. Felip, P. Garrido, B. Gaspar, M. Llombart, A. López, I. Magallón, V. M. Ibáñez, J. M. Olmos, C. Mur, A. Navarro-Ruiz, A. Pastor, M. Peiró Posadas, J. PoloRodríguez-Lescure

Producció científica: Article en revista indexada › Article › Avaluat per experts

6 Cites (Scopus)

Resum

Purpose: The increase in the prevalence "long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care. Methods: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report. Results: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions. Conclusion: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.

Idioma original	Anglès
Pàgines (de-a)	350-362
Nombre de pàgines	13
Revista	Clinical and Translational Oncology
Volum	24
Número	2
DOIs	https://doi.org/10.1007/s12094-021-02696-5
Estat de la publicació	Publicada - de febr. 2022
Publicat externament	Sí

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1007/s12094-021-02696-5

Altres arxius i enllaços

Link to publication in Scopus

Com citar-ho

Provencio, M., Romero, N., Tabernero, J., Vera, R., Baz, D. V., Arraiza, A., Camps, C., Felip, E., Garrido, P., Gaspar, B., Llombart, M., López, A., Magallón, I., Ibáñez, V. M., Olmos, J. M., Mur, C., Navarro-Ruiz, A., Pastor, A., Peiró Posadas, M., ... Rodríguez-Lescure (2022). Future care for long-term cancer survivors: towards a new model. Clinical and Translational Oncology, 24(2), 350-362. https://doi.org/10.1007/s12094-021-02696-5

@article{974528c6eba043eea33aad60f980abdc,

title = "Future care for long-term cancer survivors: towards a new model",

abstract = "Purpose: The increase in the prevalence {"}long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care. Methods: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report. Results: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions. Conclusion: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.",

keywords = "LCS patient care, Long cancer survivor, Multidisciplinary cancer care",

author = "M. Provencio and N. Romero and J. Tabernero and R. Vera and Baz, {D. V.} and A. Arraiza and C. Camps and E. Felip and P. Garrido and B. Gaspar and M. Llombart and A. L{\'o}pez and I. Magall{\'o}n and Ib{\'a}{\~n}ez, {V. M.} and Olmos, {J. M.} and C. Mur and A. Navarro-Ruiz and A. Pastor and {Peir{\'o} Posadas}, M. and J. Polo and Rodr{\'i}guez-Lescure",

note = "Funding Information: Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This project was funded by AZ. The funding party did not influence the opinion of the authors. All the authors have accepted the participation as advisers of the ASISTO group and give their consent for the publication of the document. Funding Information: Astrazeneca and the ESADE Institute for Healthcare Management. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2022",

month = feb,

doi = "10.1007/s12094-021-02696-5",

language = "English",

volume = "24",

pages = "350--362",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

publisher = "Springer-Verlag Italia s.r.l.",

number = "2",

}

Provencio, M, Romero, N, Tabernero, J, Vera, R, Baz, DV, Arraiza, A, Camps, C, Felip, E, Garrido, P, Gaspar, B, Llombart, M, López, A, Magallón, I, Ibáñez, VM, Olmos, JM, Mur, C, Navarro-Ruiz, A, Pastor, A, Peiró Posadas, M, Polo, J & Rodríguez-Lescure 2022, 'Future care for long-term cancer survivors: towards a new model', Clinical and Translational Oncology, vol. 24, núm. 2, pàg. 350-362. https://doi.org/10.1007/s12094-021-02696-5

TY - JOUR

T1 - Future care for long-term cancer survivors

T2 - towards a new model

AU - Provencio, M.

AU - Romero, N.

AU - Tabernero, J.

AU - Vera, R.

AU - Baz, D. V.

AU - Arraiza, A.

AU - Camps, C.

AU - Felip, E.

AU - Garrido, P.

AU - Gaspar, B.

AU - Llombart, M.

AU - López, A.

AU - Magallón, I.

AU - Ibáñez, V. M.

AU - Olmos, J. M.

AU - Mur, C.

AU - Navarro-Ruiz, A.

AU - Pastor, A.

AU - Peiró Posadas, M.

AU - Polo, J.

AU - Rodríguez-Lescure,

N1 - Funding Information: Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This project was funded by AZ. The funding party did not influence the opinion of the authors. All the authors have accepted the participation as advisers of the ASISTO group and give their consent for the publication of the document. Funding Information: Astrazeneca and the ESADE Institute for Healthcare Management. Publisher Copyright: © 2021, The Author(s).

PY - 2022/2

Y1 - 2022/2

N2 - Purpose: The increase in the prevalence "long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care. Methods: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report. Results: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions. Conclusion: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.

AB - Purpose: The increase in the prevalence "long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care. Methods: This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report. Results: 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions. Conclusion: The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.

KW - LCS patient care

KW - Long cancer survivor

KW - Multidisciplinary cancer care

UR - http://www.scopus.com/inward/record.url?scp=85118327923&partnerID=8YFLogxK

U2 - 10.1007/s12094-021-02696-5

DO - 10.1007/s12094-021-02696-5

M3 - Article

C2 - 34716541

AN - SCOPUS:85118327923

SN - 1699-048X

VL - 24

SP - 350

EP - 362

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 2

ER -

Future care for long-term cancer survivors: towards a new model

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho